Table 3.
Convergent validity of UCT.
| UCT Score | Correlation Coefficienta | |
|---|---|---|
| CSU | UAS28-Baseline | −0.662, P < .001 |
| CUQ2oL-1st | −0.649, P < .001 | |
| PatGA-VAS-1st | −0.756, P < .001 | |
| PhyGA-VAS-1st | 0.708, P < .001 | |
| PatGA-LS-1st | −0.763, P < .001 | |
| PhyGA-LS-1st | −0.733, P < .001 | |
| CINDU | DLQI-1st | −0.545, P < .001 |
| PatGA-VAS-1st | −0.678, P < .001 | |
| PhyGA-VAS-1st | 0.624, P < .001 | |
| PatGA-LS-1st | −0.664, P < .001 | |
| PhyGA-LS-1st | −0.774, P < .001 | |
| TOTAL | PatGA-VAS-1st | −0.741, P < .001 |
| PhyGA-VAS-1st | 0.698, P < .001 | |
| PatGA-LS-1st | −0.737, P < .001 | |
| PhyGA-LS-1st | −0.784, P < .001 |
UAS28-Baseline: the 4-weekly UAS score before the 1st visit, UAS28, UAS28-1st: the 4-weekly UAS score between the 1st and 2nd visit, UCT-1st: Urticaria control test score at the 1st visit, UCT-2nd: Urticaria control test score at the 2nd visit, CU-Q2oL-1st: Chronic urticaria quality of life questionnaire score at the 1st visit, CU-Q2oL-2nd: Chronic urticaria quality of life questionnaire score at the 2nd visit, PatGA-VAS-1st: Patient's global assessment of disease severity-visual analog scale at the 1st visit, PatGA-VAS-2nd: Patient's global assessment of disease severity-visual analog scale at the 2nd visit, PhyGA-VAS-1st: Physician's global assessment of disease control - visual analog scale at the 1st visit, PhyGA-VAS-2nd: Physician's global assessment of disease control - visual analog scale at the 2nd visit, DLQI-1st: Dermatology Life Quality Index Score at the 1st visit, DLQI-2nd: Dermatology Life Quality Index Score at the 2nd visit.
Pearson's correlation coefficient. Weak, moderate and strong correlations were defined as correlation coefficient values of <0.3, 0.3–0.6, and >0.6 respectively.